Cargando…
Computational drug design of novel COVID-19 inhibitor
BACKGROUND: In 2003, the first case of severe acute respiratory syndrome coronavirus (SARS-CoV) was recorded. Coronaviruses (CoVs) have caused a major outbreak of human fatal pneumonia. Currently, there is no specific drug or treatment for diseases caused by SARS CoV 2. Computational approach that a...
Autores principales: | Arthur, David Ebuka, Elegbe, Benjamin Osebi, Aroh, Augustina Oyibo, Soliman, Mahmoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284480/ https://www.ncbi.nlm.nih.gov/pubmed/35854796 http://dx.doi.org/10.1186/s42269-022-00892-z |
Ejemplares similares
-
Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis
por: Abdullahi, Mustapha, et al.
Publicado: (2021) -
Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies
por: Mousavi, Sarah, et al.
Publicado: (2022) -
Computer-Aided Drug Design Boosts RAS Inhibitor Discovery
por: Wang, Ge, et al.
Publicado: (2022) -
DrugDevCovid19: An Atlas of Anti-COVID-19 Compounds Derived by Computer-Aided Drug Design
por: Liu, Yang, et al.
Publicado: (2022) -
The Effect of Persuasive Design on the Adoption of Exposure Notification Apps: Quantitative Study Based on COVID Alert
por: Oyibo, Kiemute, et al.
Publicado: (2022)